These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 19342222

  • 1. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T, Liu PY, Tee AE, Haber M, Norris MD, Gleave ME, Marshall GM.
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [Abstract] [Full Text] [Related]

  • 2. Histone deacetylase inhibitors: multifunctional anticancer agents.
    Liu T, Kuljaca S, Tee A, Marshall GM.
    Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN.
    Clin Cancer Res; 2005 Dec 01; 11(23):8467-75. PubMed ID: 16322310
    [Abstract] [Full Text] [Related]

  • 4. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.
    Anticancer Drugs; 2009 Sep 01; 20(8):682-92. PubMed ID: 19606018
    [Abstract] [Full Text] [Related]

  • 5. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H.
    Oncol Rep; 2005 May 01; 13(5):885-90. PubMed ID: 15809754
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
    Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP.
    Cancer Res; 2001 May 01; 61(9):3591-4. PubMed ID: 11325825
    [Abstract] [Full Text] [Related]

  • 9. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ, Johnstone RW, Bolden JE.
    Cancer Lett; 2009 Aug 08; 280(2):125-33. PubMed ID: 19359091
    [Abstract] [Full Text] [Related]

  • 10. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H, Hara I, Kamidono S, Gleave ME.
    Clin Cancer Res; 2001 Dec 08; 7(12):4245-52. PubMed ID: 11751526
    [Abstract] [Full Text] [Related]

  • 11. Histone deacetylase inhibitors: molecular mechanisms of action.
    Xu WS, Parmigiani RB, Marks PA.
    Oncogene; 2007 Aug 13; 26(37):5541-52. PubMed ID: 17694093
    [Abstract] [Full Text] [Related]

  • 12. Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
    Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Komatsu A, Sakata H, Matsushita K, Ochiai T.
    Oncol Rep; 2007 Sep 13; 18(3):585-92. PubMed ID: 17671705
    [Abstract] [Full Text] [Related]

  • 13. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW.
    Cancer Chemother Pharmacol; 2007 Jul 13; 60(2):275-83. PubMed ID: 17124594
    [Abstract] [Full Text] [Related]

  • 14. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells.
    Nuutinen T, Suuronen T, Kyrylenko S, Huuskonen J, Salminen A.
    Neurochem Int; 2005 Dec 13; 47(8):528-38. PubMed ID: 16157419
    [Abstract] [Full Text] [Related]

  • 15. Prospects: histone deacetylase inhibitors.
    Dokmanovic M, Marks PA.
    J Cell Biochem; 2005 Oct 01; 96(2):293-304. PubMed ID: 16088937
    [Abstract] [Full Text] [Related]

  • 16. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells.
    Starkova J, Madzo J, Cario G, Kalina T, Ford A, Zaliova M, Hrusak O, Trka J.
    Clin Cancer Res; 2007 Mar 15; 13(6):1726-35. PubMed ID: 17325341
    [Abstract] [Full Text] [Related]

  • 17. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR.
    Anticancer Drugs; 2010 Oct 15; 21(9):805-13. PubMed ID: 20679890
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors.
    Marks PA, Richon VM, Miller T, Kelly WK.
    Adv Cancer Res; 2004 Oct 15; 91():137-68. PubMed ID: 15327890
    [Abstract] [Full Text] [Related]

  • 19. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
    Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R.
    Mol Ther; 2006 Dec 15; 14(6):768-78. PubMed ID: 16990052
    [Abstract] [Full Text] [Related]

  • 20. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B, Ontoria JM, Cruz JC, Rowley M, Schultz-Fademrecht C, Steinkühler C, Jones P.
    Bioorg Med Chem Lett; 2009 Jun 01; 19(11):3081-4. PubMed ID: 19410459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.